NSE - Delayed Quote INR

Dr. Lal PathLabs Limited (LALPATHLAB.NS)

Compare
2,515.70
+0.85
+(0.03%)
At close: 3:30:00 PM GMT+5:30
Loading Chart for LALPATHLAB.NS
  • Previous Close 2,514.85
  • Open 2,510.00
  • Bid --
  • Ask --
  • Day's Range 2,465.00 - 2,541.00
  • 52 Week Range 2,165.80 - 3,653.95
  • Volume 101,664
  • Avg. Volume 234,927
  • Market Cap (intraday) 209.693B
  • Beta (5Y Monthly) 0.26
  • PE Ratio (TTM) 50.26
  • EPS (TTM) 50.05
  • Earnings Date May 8, 2025 - May 12, 2025
  • Forward Dividend & Yield 36.00 (1.43%)
  • Ex-Dividend Date Feb 5, 2025
  • 1y Target Est 3,105.42

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.

www.lalpathlabs.com

4,099

Full Time Employees

March 31

Fiscal Year Ends

Recent News: LALPATHLAB.NS

View More

Performance Overview: LALPATHLAB.NS

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

LALPATHLAB.NS
15.98%
S&P BSE SENSEX (^BSESN)
3.55%

1-Year Return

LALPATHLAB.NS
11.39%
S&P BSE SENSEX (^BSESN)
1.53%

3-Year Return

LALPATHLAB.NS
5.72%
S&P BSE SENSEX (^BSESN)
24.34%

5-Year Return

LALPATHLAB.NS
94.01%
S&P BSE SENSEX (^BSESN)
173.15%

Compare To: LALPATHLAB.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LALPATHLAB.NS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    209.62B

  • Enterprise Value

    200.00B

  • Trailing P/E

    50.23

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.72

  • Price/Book (mrq)

    10.47

  • Enterprise Value/Revenue

    8.32

  • Enterprise Value/EBITDA

    26.42

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.34%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    24.04B

  • Net Income Avi to Common (ttm)

    4.17B

  • Diluted EPS (ttm)

    50.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.27B

  • Total Debt/Equity (mrq)

    9.75%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: LALPATHLAB.NS

View More

Company Insights: LALPATHLAB.NS

Research Reports: LALPATHLAB.NS

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.